Neurocrine Biosciences (NBIX) Tops Q3 EPS by 6c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mail
Get Alerts NBIX Hot Sheet
Price: $168.15 +2.00%
Financial Fact:
General and administrative: 17.49M
Today's EPS Names:
ATS, SICP, FTCO, More
Financial Fact:
General and administrative: 17.49M
Today's EPS Names:
ATS, SICP, FTCO, More
Join SI Premium – FREE
Neurocrine Biosciences (NASDAQ: NBIX) reported Q3 EPS of $0.52, $0.06 better than the analyst estimate of $0.46. Revenue for the quarter came in at $151.8 million versus the consensus estimate of $151.83 million.
For earnings history and earnings-related data on Neurocrine Biosciences (NBIX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Neurocrine Bio. (NBIX) PT Raised to $224 at Guggenheim
- Uber Q3 profit, revenue beat estimates as gross bookings jump 20%
- Bernstein SocGen on Neurocrine Bio. (NBIX): 'This latest Crenessity beat may serve as the positive inflection point'
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
